PMID- 36896896
OWN - NLM
STAT- Publisher
LR  - 20231221
IS  - 2192-5682 (Print)
IS  - 2192-5682 (Linking)
DP  - 2023 Mar 10
TI  - Preoperative Serum Albumin Level Predicts Length of Stay and Perioperative 
      Adverse Events Following Vertebral Corpectomy and Posterior Stabilization for 
      Metastatic Spine Disease.
PG  - 21925682231163814
LID - 10.1177/21925682231163814 [doi]
AB  - STUDY DESIGN: Retrospective review of a prospectively collected national 
      database. OBJECTIVES: To determine the association between preoperative serum 
      albumin levels and perioperative adverse events (AEs) following vertebral 
      corpectomy and posterior stabilization for metastatic spine disease. METHODS: The 
      2010 to 2019 American College of Surgeons' National Surgical Quality Improvement 
      (ACS-NSQIP) database was used to identify all patients undergoing vertebral 
      corpectomy and posterior stabilization for metastatic spine disease. Receiver 
      operative characteristic (ROC) curve analysis was used to determine preoperative 
      serum albumin cut-off values for predicting perioperative AEs. Low preoperative 
      serum albumin was defined as serum albumin below this cut-off value. RESULTS: A 
      total of 301 patients were included in the study. ROC curve analysis demonstrated 
      serum albumin < 3.25 g/dL as a cut-off value for predicting perioperative AEs. 
      The low serum albumin group had a higher overall perioperative AEs (P = .041), 
      longer post-operative LOS (P < .001), higher 30-day reoperation rate (P = .014), 
      and a higher in-hospital mortality rate (P = .046). Multivariate analysis 
      demonstrated that low preoperative serum albumin was associated with higher 
      perioperative AEs. CONCLUSIONS: Low serum albumin level is associated with higher 
      perioperative AEs, longer postoperative LOS, and higher rates of 30-day 
      reoperation and in-hospital mortality among patients undergoing vertebral 
      corpectomy and posterior stabilization for metastatic spine disease. Strategies 
      to improve preoperative nutritional status in patients undergoing this procedure 
      may improve these perioperative outcome measures within this surgical population. 
      LEVEL OF EVIDENCE: III.
FAU - Hirase, Takashi
AU  - Hirase T
AUID- ORCID: 0000-0001-6476-6548
AD  - Department of Orthopedic and Sports Medicine, Houston Methodist Hospital, 
      Houston, TX, USA. RINGGOLD: 23534
FAU - Taghlabi, Khaled M
AU  - Taghlabi KM
AD  - Department of Neurosurgery, Houston MethodistHospital, Houston, TX, USA. 
      RINGGOLD: 23530
FAU - Cruz-Garza, Jesus G
AU  - Cruz-Garza JG
AD  - Department of Neurosurgery, Houston MethodistHospital, Houston, TX, USA. 
      RINGGOLD: 23530
FAU - Faraji, Amir H
AU  - Faraji AH
AD  - Department of Neurosurgery, Houston MethodistHospital, Houston, TX, USA. 
      RINGGOLD: 23530
FAU - Marco, Rex A W
AU  - Marco RAW
AUID- ORCID: 0000-0003-3393-1672
AD  - Department of Orthopedic and Sports Medicine, Houston Methodist Hospital, 
      Houston, TX, USA. RINGGOLD: 23534
FAU - Saifi, Comron
AU  - Saifi C
AD  - Department of Orthopedic and Sports Medicine, Houston Methodist Hospital, 
      Houston, TX, USA. RINGGOLD: 23534
LA  - eng
PT  - Journal Article
DEP - 20230310
PL  - England
TA  - Global Spine J
JT  - Global spine journal
JID - 101596156
OTO - NOTNLM
OT  - adverse events
OT  - albumin
OT  - corpectomy
OT  - metastatic spine disease
OT  - posterior instrumentation
COIS- Declaration of Conflicting InterestsThe author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Takashi Hirase, Khaled Taghlabi, Jesus Cruz-Garza, 
      and Amir Faraji has no conflicts of interests to disclose. Rex Marco has the 
      following disclosures: DePuy, A Johnson & Johnson Company: Paid presenter or 
      speaker Globus Medical: IP royalties. Comron Saifi has the following disclosures: 
      Acquisition of Vertera Inc. by NuVasive' Shares: Stock or stock Options. Alphatec 
      Spine: Stock or stock Options. Nuvasive: Paid consultant. Restor3d: Stock or 
      stock Options.
EDAT- 2023/03/11 06:00
MHDA- 2023/03/11 06:00
CRDT- 2023/03/10 06:53
PHST- 2023/03/11 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
PHST- 2023/03/10 06:53 [entrez]
AID - 10.1177/21925682231163814 [doi]
PST - aheadofprint
SO  - Global Spine J. 2023 Mar 10:21925682231163814. doi: 10.1177/21925682231163814.